What is the most effective myopia treatment for children?

Combination therapy (e.g., orthokeratology plus atropine) achieves the highest efficacy at approximately 68% slowing of axial length growth. Among single-modality treatments, Stellest® lenses (67%) and high-dose atropine 0.05% (58%) show the highest individual efficacy. The best option depends on age, progression rate, and the child's ability to comply with contact lens wear.

At what age can a child start myopia treatment?

MiSight® 1 day contact lenses are approved from age 8. Atropine drops can be used from age 3–4 under close monitoring. Orthokeratology is typically started from age 6–8. Stellest® spectacle lenses have no minimum age restriction and are suitable for younger children. Earlier treatment consistently produces better long-term outcomes.

Do myopia treatments really work?

Yes — multiple large randomised controlled trials have demonstrated significant slowing of myopia progression. MiSight® reduced axial length growth by 55% over 6 years (Chamberlain 2019). Stellest® showed 67% reduction over 2 years (Bao 2022). Low-dose atropine 0.01% reduces progression by approximately 30–50% (ATOM2, LAMP studies).

Home › Resources › Best myopia treatment for children

MyopiaTracker Clinical Team

Reviewed by B. Vasudevan, BSOptom, PhD, MBA · Last updated: April 2026

What Is the Best Myopia Treatment for Children?

Short answer: No single treatment is "best" for every child. Most options slow myopia by 30–67%, but the right choice depends on age, how fast the myopia is progressing, and whether the child can wear contact lenses. A clinician can compare projected outcomes for your child's specific data.

For clinicians: Looking for a side-by-side efficacy comparison with RCT references? See the clinical comparison →

Efficacy by treatment — what the trials show

The following figures represent slowing of axial length growth compared to a control group, drawn from primary randomised controlled trials.

Combination therapy †

68%

Stellest® (HALT)

67%

Atropine 0.05%

58%

MiSight® 1 day

55%

MiyoSmart® (DIMS)

52%

Ortho-K

50%

Atropine 0.025%

45%

Atropine 0.01%

30%

Outdoor / behavioural

18%

† Combination therapy is a modeled composite estimate — no single RCT directly validates combined efficacy. Individual results vary. Sources: Chamberlain 2019, Bao 2022, Chia 2012 (ATOM2), Yam 2019 (LAMP), Lam 2020.

Quick takeaway: Faster eye growth = higher long-term risk. Treatments that achieve 50%+ slowing meaningfully reduce the chance of reaching high myopia (above −6D) and the associated risks of retinal detachment, glaucoma, and macular degeneration.

The main options explained

MiSight® 1 day contact lenses

55%

slowing of axial growth (Chamberlain 2019, 6-year RCT)

Daily disposable

FDA-approved for myopia control. Suitable from age 8. Dual-focus design creates peripheral myopic defocus. No handling of lenses overnight.

Stellest® lenses (HALT technology)

67%

slowing of axial growth (Bao 2022, JAMA Ophthalmol)

Spectacle lenses

No contact lens handling. Suitable from school age. Must be worn ≥12 hours/day for full effect. Well-tolerated by younger children.

Orthokeratology (Ortho-K)

50%

slowing of axial growth (pooled meta-analysis)

Overnight lenses

Rigid lenses worn overnight — child wakes with clear vision without glasses. Suitable from ~age 7. Requires careful hygiene. Effective and reversible.

Atropine eye drops

30–58%

slowing depending on concentration (ATOM2, LAMP trials)

Once-daily drops

Low-dose 0.01% has fewest side effects. Higher doses more effective but cause more light sensitivity and blur. Often combined with other treatments.

How to choose: a decision framework

Situation	First consider	Why
Child under 8, fast progressor	Stellest® or atropine 0.01%	No minimum age for spectacles; drops well tolerated
Age 8–12, moderate progression	MiSight® 1 day or Stellest®	Both have strong RCT evidence; contact lens readiness varies
Fast progression, any age	Combination therapy	Highest achievable efficacy; stacks multiple mechanisms
Child prefers no daytime glasses/lenses	Orthokeratology	Clear unaided vision during the day; worn only overnight
Allergies or poor contact lens tolerance	Stellest® + atropine 0.01%	No contact lens required; additive effect

Not sure what to do next?

MyopiaTracker lets you enter your child's axial length measurements and see projected outcomes for each treatment side by side — based on their actual growth data, not averages. It takes 60 seconds. Free, no login required.

Find the best option for your child →

What about glasses? Do they help?

Standard single-vision glasses and contact lenses correct vision — they do not slow eye growth. The eye continues to lengthen at the same rate regardless of wearing standard correction. This is why the treatments above use optical designs specifically engineered to signal the eye to slow its growth.

Starting treatment: earlier is better

Every year of untreated fast progression adds permanently to lifetime axial length. A child who reaches −4.00D at age 14 versus age 20 will have had 6 additional years of rapid growth — and the associated structural changes are irreversible. The evidence strongly supports treating early, even when progression appears "only moderate."

Compare treatment outcomes for your child's data

Enter age, axial length, and prior measurements. Get a 9-modality comparison showing projected AL at age 18 for each treatment option. No signup, no cost.

Compare treatments now → MiSight® vs Stellest® →

This page is for educational purposes only and does not constitute medical advice. MyopiaTracker is a decision-support tool — not a diagnostic device or prescribing guide. All efficacy figures are from published RCTs; individual outcomes vary. MiSight® is a registered trademark of CooperVision. Stellest® is a registered trademark of Essilor. MiyoSmart® is a registered trademark of Hoya. Consult a qualified eye care professional for personalised treatment decisions.